Loading
A growth receptor on connective-tissue and blood-vessel cells. Imatinib works in rare cancers driven by PDGFRB fusions, such as dermatofibrosarcoma protuberans and some chronic myeloid neoplasms with eosinophilia.
Platelet-derived growth factor receptor beta signals in fibroblasts, pericytes and smooth muscle. The COL1A1::PDGFB fusion of dermatofibrosarcoma protuberans drives the receptor through its own ligand, and PDGFRB rearrangements define a group of myeloid and lymphoid neoplasms with eosinophilia; both respond to imatinib, which inhibits PDGFRB alongside KIT, ABL1 and PDGFRA. Sunitinib, pazopanib and other multi-kinase inhibitors also block it, contributing to their anti-angiogenic effect through pericytes. In most solid tumours PDGFRB is a stromal rather than a tumour-cell target.
In plain words · A growth receptor on connective-tissue and blood-vessel cells. Imatinib works in rare cancers driven by PDGFRB fusions, such as dermatofibrosarcoma protuberans and some chronic myeloid neoplasms with eosinophilia.
A growth receptor on connective-tissue and blood-vessel cells. Imatinib works in rare cancers driven by PDGFRB fusions, such as dermatofibrosarcoma protuberans and some chronic myeloid neoplasms with eosinophilia.
Receptor tyrosine kinase of mesenchymal cells and pericytes; oncogenic through fusions in dermatofibrosarcoma protuberans and myeloid neoplasms with eosinophilia.
No product in this corpus aims at PDGFRB yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; the 2 medicines aimed at it (Imatinib, Sunitinib) act on the wild-type protein, so normal tissue is exposed and the therapeutic window comes from the tumour's faster division or its dependence on the protein. HPA PDGFRB: RNA low tissue specificity; high antibody staining in 2 normal tissues; highest cancer staining glioma (3 of 11 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Sarcomas (soft tissue, bone, GIST), Leukaemia); approvals of single-target medicines aimed at it also list Skin cancer (all types), not counted; Open Targets associates it with 14 specific cancer types at or above 0.5 (myofibromatosis, infantile, 1, infantile myofibromatosis, hepatocellular carcinoma, gastrointestinal stromal tumor, chronic myeloid leukemia, acute myeloid leukemia and more). (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas PDGFRB tissue; Open Targets ENSG00000113721 associations
First described 1988. Earliest sequence paper UniProt cites for the protein: Gronwald R.G.K. et al, Proc. Natl. Acad. Sci. U.S.A, 1988, "Cloning and expression of a cDNA coding for the human platelet-derived growth factor receptor: evidence for more than one receptor class". Source.
Receptor tyrosine kinase of mesenchymal cells and pericytes; oncogenic through fusions in dermatofibrosarcoma protuberans and myeloid neoplasms with eosinophilia.
RNA: low tissue specificity, detected in many normal tissues.
Medium: Breast, Cerebral cortex, Endometrium, Kidney, Ovary, Placenta.
Medium only: colorectal cancer, ovarian cancer, testis cancer.
HPA PDGFRB tissue · HPA PDGFRB pathology · HPA protein class: CD markers, FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"PDGFRB" OR ABSTRACT:"PDGFRB") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PDGFRB, not a curated reading list.
Shares Dermatofibrosarcoma protuberans, Sarcomas (soft tissue, bone, GIST).
Shares Dermatofibrosarcoma protuberans, Imatinib.
Shares Dermatofibrosarcoma protuberans, Sarcomas (soft tissue, bone, GIST).
Shares Dermatofibrosarcoma protuberans, Sunitinib, Imatinib, Sarcomas (soft tissue, bone, GIST).